Literature DB >> 16325240

Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.

Anne Beate Vereide1, Turid Kaino, Georg Sager, Marit Arnes, Anne Ørbo.   

Abstract

OBJECTIVES: The effect on progesterone and estrogen receptor expression in glands and stroma after two different treatment regimens of endometrial hyperplasia was determined.
METHODS: Pre- and post-treatment paraffin-embedded endometrial hyperplasia specimens from women treated with levonorgestrel (LNG) intrauterine device (n = 21) and women treated with 10 mg medroxyprogesterone acetate (MPA) for 10 days per cycle (n = 29) were examined immunohistochemically and evaluated by H-score (a semi-quantitative microscopical method evaluating staining intensity and number of stained cells, scale 0-3) for changes in expression of PRA (progesterone receptor A), PRB (progesterone receptor B), ER-alpha (estrogen receptor-alpha), ER-beta (estrogen receptor-beta) and AR (androgen receptors) after 3 months of treatment.
RESULTS: All the patients in the LNG IUD group responded to treatment with no sign of hyperplasia after 3 months, while only about half of the patients given MPA orally responded. Expression of PRA, PRB, ER-alpha and ER-beta were markedly reduced after progestin treatment in both treatment groups but the reduction was much more pronounced in the LNG group (H-score for PRA was reduced from 2.61 to 0.11 in glands and from 2.26 to 0.09 in stroma in LNG group. Corresponding reduction for PRB in the LNG group was from 1.96 to 0.11 and from 0.83 to 0.01. PRA was reduced from 2.53 to 1.78 in glands and from 1.93 to 1.30 in stroma in the MPA group. Corresponding reduction for PRB in the MPA group was from 2.02 to 1.25 in glands and from 0.80 to 0.34 in stroma). Weak and focal stromal expression of AR was demonstrated in 22% of the specimens before but not after therapy. There was a statistically significant reduction in both PR and ER among the responders whereas non-responders showed no statistical change after treatment.
CONCLUSION: The present study shows that LNG IUD causes an almost complete down-regulation (lack of immunohistochemical expression) of PR expression and a considerable down-regulation of ER expression in both glands and stroma. The changes in receptor expression were markedly less pronounced after treatment with intermittent oral MPA. The differences in receptor expression among responders and non-responders might serve as possible markers for therapy response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325240     DOI: 10.1016/j.ygyno.2005.10.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

1.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

2.  A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.

Authors:  Linda R Duska; Gina R Petroni; Heather Lothamer; William Faust; Jan H Beumer; Susan M Christner; Anne M Mills; Paula M Fracasso; Sarah J Parsons
Journal:  Cancer Chemother Pharmacol       Date:  2018-12-08       Impact factor: 3.333

3.  Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Authors:  Lyndsay V Rhodes; Sarah P Short; Nicole F Neel; Virgilio A Salvo; Yun Zhu; Steven Elliott; Yongkun Wei; Dihua Yu; Menghong Sun; Shannon E Muir; Juan P Fonseca; Melyssa R Bratton; Chris Segar; Syreeta L Tilghman; Tammy Sobolik-Delmaire; Linda W Horton; Snjezana Zaja-Milatovic; Bridgette M Collins-Burow; Scott Wadsworth; Barbara S Beckman; Charles E Wood; Suzanne A Fuqua; Kenneth P Nephew; Paul Dent; Rebecca A Worthylake; Tyler J Curiel; Mien-Chie Hung; Ann Richmond; Matthew E Burow
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

4.  The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women.

Authors:  Seo Yeong Lee; Mi Kyoung Kim; Hyun Park; Bo Sung Yoon; Seok Ju Seong; Jin Hee Kang; Hye Sun Jun; Chong Taik Park
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

5.  Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.

Authors:  Navdeep Pal; Russell R Broaddus; Diana L Urbauer; Nyla Balakrishnan; Andrea Milbourne; Kathleen M Schmeler; Larissa A Meyer; Pamela T Soliman; Karen H Lu; Pedro T Ramirez; Lois Ramondetta; Diane C Bodurka; Shannon N Westin
Journal:  Obstet Gynecol       Date:  2018-01       Impact factor: 7.661

Review 6.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

Review 7.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

8.  Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium.

Authors:  Tonia L Hermon; Alicia B Moore; Linda Yu; Grace E Kissling; Frank J Castora; Darlene Dixon
Journal:  Virchows Arch       Date:  2008-10-14       Impact factor: 4.064

9.  Differential effects of synthetic progestagens on neuron survival and estrogen neuroprotection in cultured neurons.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Mol Cell Endocrinol       Date:  2014-01-11       Impact factor: 4.102

10.  Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium.

Authors:  M-L Alvarez Gonzalez; C Galant; F Frankenne; M Nisolle; S Labied; J-M Foidart; E Marbaix; A Béliard
Journal:  Hum Reprod       Date:  2008-12-17       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.